Actemra® (tocilizumab)

BL 125276 [BL 125472]

Actemra® (tocilizumab)

BL 125276 [BL 125472]

U.S. License Holder:

Genentech

Date of License:

January-08-2010 [October-21-2013]

Last Update:

Sep-23-2023

approved_indications FDA-Approved Indications

ACTEMRA (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

Rheumatoid Arthritis (RA): Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs);

Giant Cell Arteritis (GCA): Adult patients with giant cell arteritis;

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD);

Polyarticular Juvenile Idiopathic Arthritis (PJIA): Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis;

Systemic Juvenile Idiopathic Arthritis (SJIA): Patients 2 years of age and older with active systemic juvenile idiopathic arthritis;

Cytokine Release Syndrome (CRS): Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome;

Coronavirus Disease 2019 (COVID-19): Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

approved_indications aBLA / 505(b)(2) Activity

aBLA / 505(b)(2) Accepted by FDA

MSB11456: Fresenius Kabi (August-2022) BIIB800: Biogen / Bio-Thera (December-2022)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2021-01024

U.S. Patent No.
7,521,052 (Methods for Treating Interleukin-6 Related Diseases)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2021-01025

U.S. Patent No.
10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2021-01288

U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2021-01336

U.S. Patent No.
10,874,677 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Other (Drug Delivery Device)

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Other (Drug Delivery Device)

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2021-01542

U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Genentech, Inc.; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, Inc.; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2022-00201

U.S. Patent No.
9,750,752 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, LLC; Fresenius SE & Co. KGaA

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Settled After Institution

IPR2022-00578

U.S. Patent No.
8,580,264 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.; Genentech, Inc.

Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co. Ltd.; Celltrion Healthcare USA, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

IPR Status
Final Written Decision (All Challenged Claims Unpatentable)

IPR2022-00579

U.S. Patent No.
10,874,677 (Subcutaneously Administered Anti-IL6 Receptor Antibody)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.; Genentech, Inc.

Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co. Ltd.; Celltrion Healthcare USA, Inc.

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Other (Drug Delivery Device)

§ 102 Challenge Instituted
Y

§ 103 challenge
Y

Claim Types Challenged Under § 103
Other (Drug Delivery Device)

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

IPR Status
Final Written Decision (All Challenged Claims Unpatentable)

IPR2022-01065

U.S. Patent No.
10,231,981 (Subcutaneously Administered Anti-IL6 Receptor Antibody for Treatment of Juvenile Idiopathic Arthritis)

Patent Owner
Chugai Seiyaku Kabushiki Kaisha; Hoffmann-La Roche Inc.

Petitioner(s)
Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi AG; Fresenius Kabi Deutschland GmbH; Fresenius Kabi Pharmaceuticals Holding, LLC; Fresenius SE & Co. KGaA

§ 102 Challenge
Y

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Settled Prior to Institution Decision

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Settled Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled Prior to Institution Decision)

IPR Status
Settled Prior to Institution Decision

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:23-cv-11573 (D. Mass.)

U.S. Patent Nos.
7,332,289 (Method of Purifying Protein) 7,521,052 (Methods for Treating Interleukin-6 Related Diseases) 8,398,980 (Subtypes of Humanized Antibody Against Interleuken-6 Receptor) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,734,800 (Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 9,714,293 (Production of Proteins in Glutamine-Free Cell Culture Media) 9,902,777 (Methods for Producing Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells) 10,501,769 (Method for the Production of a Glycosylated Immunoglobulin) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate) 10,829,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,982,003 (Production of Proteins in Glutamine-Free Cell Culture Media) 11,021,728 (Method for the Production of a Glycosylated Immunoglobulin) 11,078,294 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 11,136,610 (Method for the Production of a Glycosylated Immunoglobulin) 11,377,678 (Method for the Production of a Glycosylated Immunoglobulin)

Plaintiffs
Genentech, Inc.; Chugai Pharmaceutical Co., Ltd.; Hoffmann-La Roche Inc.

Defendants
Biogen MA Inc.; Bio-Thera Solutions, Ltd.

Status
Case Ongoing

BPCIA
Y

Related News

Venable’s BiologicsHQ Monthly Injection – August 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 12, 2023
Spotlight On: Actemra® (tocilizumab)
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
August 31, 2023
Venable’s BiologicsHQ Monthly Injection – July 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 15, 2023
Venable’s BiologicsHQ Monthly Injection – June 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 15, 2023
Venable’s BiologicsHQ Monthly Injection – May 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 13, 2023
Venable’s BiologicsHQ Monthly Injection – April 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 8, 2023
Venable’s BiologicsHQ Monthly Injection – March 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 10, 2023
The State of Biosimilars in 2023
April Breyer Menon Ha Kung Wong
March 17, 2023
Venable’s BiologicsHQ Monthly Injection – February 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 15, 2023
Venable’s BiologicsHQ Monthly Injection – December 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2023
Venable’s BiologicsHQ Monthly Injection – October 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
November 14, 2022
Venable’s BiologicsHQ Monthly Injection – August 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 8, 2022
Venable’s BiologicsHQ Monthly Injection – June 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 8, 2022
Venable’s BiologicsHQ Monthly Injection – March 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 18, 2022
Venable’s BiologicsHQ Monthly Injection – February 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 8, 2022
Venable’s BiologicsHQ Monthly Injection – September 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
October 12, 2021
Venable’s BiologicsHQ Monthly Injection – August 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
September 8, 2021
Venable’s BiologicsHQ Monthly Injection – June 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 13, 2021

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha